Grant: Operating Grant: Women's Health Clinical Mentorship Grant
University of Toronto
$49,985.00
Genetic Testing in Females with Ovarian Cancer: Impact of Reflexive Tumour Genetic Testing on Clinical Care
FY 2019-20
Summary
Ovarian cancer is the deadliest of all gynecologic cancers and the 5th leading cause of cancer death in women. Ovarian cancers can be caused by genetic changes (mutations). Most mutations occur in the BRCA1 and BRCA2 genes, which are inherited from a parent (germline) or develop in a tumour (somatic). Genetic testing is very important in ovarian cancer because patients with germline or somatic BRCA mutations can have targeted treatment with drugs called PARP inhibitors. In Ontario, all ovarian cancer patients have reflexive BRCA tumour genetic testing (RTGT). This means that BRCA genetic testing is completed automatically on all ovarian tumours as part of ovarian cancer surgery. RTGT gives ovarian cancer patients genetic information quickly so their doctors can decide the best cancer treatment. A second germline genetic test (blood test) is still needed to tell patients if there is a hereditary cancer risk in their family. RTGT can improve cancer care but its effects on patient psychological response and use of germline genetic testing are unknown.
This study will examine the quality of patient care associated with RTGT in a group of ovarian cancer patients. Researchers will measure the patient psychological impact of RTGT and examine the effect of RTGT on use of germline genetic testing. To measure the patient impact, ovarian cancer patients who received RTGT results will be asked to fill in surveys about their experience. To look at changes in the use of germline genetic testing, researchers will compare the rate of referral and patient uptake of germline genetic testing in the year before and after the start of RTGT.
The results of this study will be used to develop RTGT processes at hospitals around the world to make sure ovarian cancer patients and their family members get the information and support they need. This will reduce gaps in the care of ovarian cancer patients, help to find families with a hereditary cancer risk, and prevent ovarian cancer.
Department
Program
Operating Grant: Women's Health Clinical Mentorship Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
415541
Name
Metcalfe Kelly A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Women's Health Clinical Mentorship Grant
Projecttitle
Genetic Testing in Females with Ovarian Cancer: Impact of Reflexive Tumour Genetic Testing on Clinical Care
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$49,985
Cihrequipment2
$0
Programname2
Operating Grant: Women's Health Clinical Mentorship Grant
Keyworddelim
Brca; Genetic Counselling; Gynecology; Health Service; Models Of Care; Ovarian Cancer; Patient Reported Outcomes; Women'S Health
Abstract
Ovarian cancer is the deadliest of all gynecologic cancers and the 5th leading cause of cancer death in women. Ovarian cancers can be caused by genetic changes (mutations). Most mutations occur in the BRCA1 and BRCA2 genes, which are inherited from a parent (germline) or develop in a tumour (somatic). Genetic testing is very important in ovarian cancer because patients with germline or somatic BRCA mutations can have targeted treatment with drugs called PARP inhibitors. In Ontario, all ovarian cancer patients have reflexive BRCA tumour genetic testing (RTGT). This means that BRCA genetic testing is completed automatically on all ovarian tumours as part of ovarian cancer surgery. RTGT gives ovarian cancer patients genetic information quickly so their doctors can decide the best cancer treatment. A second germline genetic test (blood test) is still needed to tell patients if there is a hereditary cancer risk in their family. RTGT can improve cancer care but its effects on patient psychological response and use of germline genetic testing are unknown.
This study will examine the quality of patient care associated with RTGT in a group of ovarian cancer patients. Researchers will measure the patient psychological impact of RTGT and examine the effect of RTGT on use of germline genetic testing. To measure the patient impact, ovarian cancer patients who received RTGT results will be asked to fill in surveys about their experience. To look at changes in the use of germline genetic testing, researchers will compare the rate of referral and patient uptake of germline genetic testing in the year before and after the start of RTGT.
The results of this study will be used to develop RTGT processes at hospitals around the world to make sure ovarian cancer patients and their family members get the information and support they need. This will reduce gaps in the care of ovarian cancer patients, help to find families with a hereditary cancer risk, and prevent ovarian cancer.
Competitiondate
201910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Metcalfe, Kelly A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $49,985~ $0~